Stock Research for OMER


Featured Broker: Ally Invest

Get the due diligence for another stock.


OMER Stock Chart & Research Data

The OMER chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OMER chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


OMER Due diligence Resources & Stock Charts

The OMER stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OMER Detailed Price Forecast - CNN Money CNN View OMER Detailed Summary - Google Finance
Yahoo View OMER Detailed Summary - Yahoo! Finance Zacks View OMER Stock Research & Analysis -

Stock Analysis

TradeIdeas View OMER Trends & Analysis - Trade-Ideas Barrons View OMER Major Holders - Barrons
NASDAQ View OMER Call Transcripts - NASDAQ Seeking View OMER Breaking News & Analysis - Seeking Alpha
Spotlight View OMER Annual Report - OTC Report View OMER OTC Short Report -
TradeKing View OMER Fundamentals - TradeKing Charts View OMER SEC Filings - Bar Chart
WSJ View Historical Prices for OMER - The WSJ Morningstar View Performance/Total Return for OMER - Morningstar
MarketWatch View the Analyst Estimates for OMER - MarketWatch CNBC View the Earnings History for OMER - CNBC
StockMarketWatch View the OMER Earnings - StockMarketWatch MacroAxis View OMER Buy or Sell Recommendations - MacroAxis
Bullish View the OMER Bullish Patterns - American Bulls Short Pains View OMER Short Pain Metrics -

Social Media Mentions

StockTwits View OMER Stock Mentions - StockTwits PennyStocks View OMER Stock Mentions - PennyStockTweets
Twitter View OMER Stock Mentions - Twitter Invest Hub View OMER Investment Forum News - Investor Hub
Yahoo View OMER Stock Mentions - Yahoo! Message Board Seeking Alpha View OMER Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for OMER - Insider Cow View Insider Transactions for OMER - Insider Cow
CNBC View OMER Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OMER - OTC Markets
Yahoo View Insider Transactions for OMER - Yahoo! Finance NASDAQ View Institutional Holdings for OMER - NASDAQ

Stock Charts

FinViz View OMER Stock Insight & Charts - StockCharts View OMER Investment Charts -
BarChart View OMER Stock Overview & Charts - BarChart Trading View View OMER User Generated Charts - Trading View

Latest Financial News for OMER

Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
Posted on Tuesday July 17, 2018

Omeros Corporation (OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s dopamine levels, widely recognized as central to both addictive and compulsive disorders. With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS527 is nicotine addiction.

Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks
Posted on Friday July 13, 2018

LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at For today, observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
Posted on Wednesday June 27, 2018

Omeros Corporation (OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents internationally directed to PDE7 inhibitors for the treatment of all addictions and compulsive disorders.

Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Tuesday June 26, 2018

NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.